Remove trial restrictions ▶ Start for $1

Serving leading biopharmaceutical companies globally:

Mallinckrodt
Colorcon
Merck
Dow
Baxter
Johnson and Johnson

Last Updated: November 27, 2022

CLINICAL TRIALS PROFILE FOR RITALIN LA


✉ Email this page to a colleague

« Back to Dashboard

▶ Start for $1
Remove trial restrictions


All Clinical Trials for Ritalin La

Trial ID Title Status Sponsor Phase Start Date Summary
NCT00018863 ↗ Treatment of Attention Deficit Hyperactivity Disorder in Preschool-Age Children (PATS) Completed National Institute of Mental Health (NIMH) Phase 3 2001-04-01 This research focuses on the treatment of Attention Deficit Hyperactivity Disorder (ADHD) in very young children. The medication being used is methylphenidate (Ritalin); it is being studied to determine its safety and how well it works to treat ADHD in preschool-age children (3-5.5 year olds).
NCT00018863 ↗ Treatment of Attention Deficit Hyperactivity Disorder in Preschool-Age Children (PATS) Completed New York State Psychiatric Institute Phase 3 2001-04-01 This research focuses on the treatment of Attention Deficit Hyperactivity Disorder (ADHD) in very young children. The medication being used is methylphenidate (Ritalin); it is being studied to determine its safety and how well it works to treat ADHD in preschool-age children (3-5.5 year olds).
NCT00025779 ↗ Methylphenidate in Children and Adolescents With Pervasive Developmental Disorders Completed National Institute of Mental Health (NIMH) N/A 2001-10-01 This study will evaluate the efficacy and safety of methylphenidate for treating hyperactivity, impulsiveness, and distractibility in 60 children and adolescents with Pervasive Developmental Disorders (PDD). Methylphenidate (Ritalin)is approved by the Food and Drug Administration for the treatment of children and adolescents with Attention Deficit Hyperactivity Disorder (ADHD). Data supporting its safety and effectiveness in treating ADHD symptoms in PDD are limited. Children and adolescents who do not show a positive response to methylphenidate will be invited to participate in a pilot study of the non-stimulant medication guanfacine (Tenex).
NCT00129467 ↗ Methylphenidate for Depressed Cancer Patients Receiving Palliative Care Completed Oregon Health and Science University N/A 2005-02-01 The purpose of this study is to determine whether methylphenidate is an effective treatment for depression and to document the safety and tolerability of methylphenidate in combination with an Selective Serotonin Reuptake Inhibitor (SSRI) in SSRI treated, terminally ill, hospice and palliative care cancer patients. The investigators hypothesize that depressed hospice and palliative care patients will be more likely to have a 50% reduction in scores on a clinical measure of depression after treatment with Methylphenidate plus an SSRI compared to those patients who are taking a placebo plus an SSRI.
NCT00129467 ↗ Methylphenidate for Depressed Cancer Patients Receiving Palliative Care Completed US Department of Veterans Affairs N/A 2005-02-01 The purpose of this study is to determine whether methylphenidate is an effective treatment for depression and to document the safety and tolerability of methylphenidate in combination with an Selective Serotonin Reuptake Inhibitor (SSRI) in SSRI treated, terminally ill, hospice and palliative care cancer patients. The investigators hypothesize that depressed hospice and palliative care patients will be more likely to have a 50% reduction in scores on a clinical measure of depression after treatment with Methylphenidate plus an SSRI compared to those patients who are taking a placebo plus an SSRI.
NCT00129467 ↗ Methylphenidate for Depressed Cancer Patients Receiving Palliative Care Completed VA Office of Research and Development N/A 2005-02-01 The purpose of this study is to determine whether methylphenidate is an effective treatment for depression and to document the safety and tolerability of methylphenidate in combination with an Selective Serotonin Reuptake Inhibitor (SSRI) in SSRI treated, terminally ill, hospice and palliative care cancer patients. The investigators hypothesize that depressed hospice and palliative care patients will be more likely to have a 50% reduction in scores on a clinical measure of depression after treatment with Methylphenidate plus an SSRI compared to those patients who are taking a placebo plus an SSRI.
>Trial ID >Title >Status >Phase >Start Date >Summary

Clinical Trial Conditions for Ritalin La

Condition Name

Condition Name for Ritalin La
Intervention Trials
Attention Deficit Hyperactivity Disorder 25
Healthy 10
Attention Deficit Disorder With Hyperactivity 7
Apathy 5
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Condition MeSH

Condition MeSH for Ritalin La
Intervention Trials
Attention Deficit Disorder with Hyperactivity 46
Hyperkinesis 35
Disease 24
Fatigue 9
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Clinical Trial Locations for Ritalin La

Trials by Country

Trials by Country for Ritalin La
Location Trials
United States 101
Israel 18
Canada 11
Netherlands 4
Switzerland 3
This preview shows a limited data set
Subscribe for full access, or try a Trial

Trials by US State

Trials by US State for Ritalin La
Location Trials
California 13
Texas 10
Massachusetts 10
Maryland 8
Ohio 8
This preview shows a limited data set
Subscribe for full access, or try a Trial

Clinical Trial Progress for Ritalin La

Clinical Trial Phase

Clinical Trial Phase for Ritalin La
Clinical Trial Phase Trials
Phase 4 35
Phase 3 14
Phase 2/Phase 3 5
[disabled in preview] 32
This preview shows a limited data set
Subscribe for full access, or try a Trial

Clinical Trial Status

Clinical Trial Status for Ritalin La
Clinical Trial Phase Trials
Completed 67
Unknown status 20
Terminated 13
[disabled in preview] 18
This preview shows a limited data set
Subscribe for full access, or try a Trial

Clinical Trial Sponsors for Ritalin La

Sponsor Name

Sponsor Name for Ritalin La
Sponsor Trials
National Institute of Mental Health (NIMH) 8
Massachusetts General Hospital 8
Shalvata Mental Health Center 6
[disabled in preview] 13
This preview shows a limited data set
Subscribe for full access, or try a Trial

Sponsor Type

Sponsor Type for Ritalin La
Sponsor Trials
Other 160
NIH 23
Industry 15
[disabled in preview] 8
This preview shows a limited data set
Subscribe for full access, or try a Trial

Make Better Decisions: Try a trial or see plans & pricing

Serving leading biopharmaceutical companies globally:

Medtronic
Baxter
McKinsey
Dow
Express Scripts
McKesson

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.